As a result of the early payment from Amylin, Eli Lilly raised its 2012 reported earnings guidance to $3.72 - $3.82 per share from $3.29 - $3.39 per share. Eli Lilly expects third quarter reported results to be boosted by about 43 cents due to the recognition of the additional income. The company also expects to recognize income of 25 cents per share in 2013 related to the transfer of exenatide commercial rights outside the US to Amylin. Amylin has also repaid a $165 million loan plus interest. Eli Lilly, meanwhile, maintained its adjusted earnings outlook of $3.30 - $3.40 per share on revenues of $21.8 - $22.8 billion. The Zacks Consensus Estimate currently stands at $3.38 per share. While the loss of Zyprexa exclusivity is expected to impact revenues by more than $3 billion, products like Cymbalta, Cialis, Humalog, Alimta and Forteo are expected to continue performing well. Moreover, new products like Effient, Axiron and Tradjenta should also contribute to revenues.